cannabis indica

Doença de Alzheimer

termo de indexação original: Alzheimer's Disease

O acervo do Cannabis Indica reúne 233 estudos científicos que tocam a condição Doença de Alzheimer, publicados entre 1890 e 2024. Pela leitura automatizada, 209 (90%) foram classificados como favoráveis, 20 (9%) como inconclusivos e 4 (2%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (110 estudos), seguido de estudo em animais (54). Os compostos mais presentes são Anandamida (AEA), Endocanabinoide (não especificado) e 2-Araquidonoilglicerol (2-AG). Aparece com frequência ao lado de Doenças Neurodegenerativas, Inflamação e Doença de Parkinson.

Estudos indexados
233
Período coberto
1890–2024
Favoráveis
209 · 90%
Inconclusivos
20 · 9%
Desfavoráveis
4 · 2%
Termo original
Alzheimer's Disease

O acervo em números

Tipo de estudo

Metanálise110
Estudo em Animais54
Estudo Laboratorial42
Ensaio Clínico Duplo-Cego12
Metanálise Clínica11
Ensaio Clínico4

Direção do resultado

Favorável209
Inconclusivo20
Desfavorável4

Por década

1890s1
1990s3
2000s17
2010s65
2020s147

233 estudos

Filtrar e buscar no acervo →
  1. 2024

    Alzheimer's disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging

  2. 2024

    Cannabidiol for behavior symptoms in Alzheimer’s disease (CANBiS-AD): a randomized, double-blind, placebo-controlled trial

    FavorávelEnsaio ClínicoAnsiedadeTranstornos de ComportamentoDemênciaCBD Farmacêutico
  3. 2024

    Δ9-Tetrahydrocannabinol (THC): A Critical Overview of Recent Clinical Trials and Suggested Guidelines for Future Research

  4. 2023

    Biotechnological Fungal Platforms for the Production of Biosynthetic Cannabinoids

    FavorávelEstudo LaboratorialDorCâncerInflamaçãoTetraidrocanabinol (THC)THC Farmacêutico+25
  5. 2023

    Cannabichromene Induces Neuronal Differentiation in NSC-34 Cells: Insights from Transcriptomic Analysis

    FavorávelEstudo LaboratorialTetraidrocanabinol (THC)Canabicromeno (CBC)+1
  6. 2023

    Cannabidiol-Loaded Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Paclitaxel-Induced Peripheral Neuropathy

    FavorávelEstudo LaboratorialCâncerInflamaçãoEstresse OxidativoTHC Farmacêutico+12
  7. 2023

    Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance

  8. 2023

    Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance

    FavorávelMetanáliseCâncerInflamaçãoAnsiedadeCanabigerol (CBG)Canabinol (CBN)+20
  9. 2023

    Effects of Chronic, Low-Dose Cannabinoids, Cannabidiol, Delta-9-Tetrahydrocannabinol and a Combination of Both, on Amyloid Pathology in the 5xFAD Mouse Model of Alzheimer's Disease

    InconclusivoEstudo em AnimaisTHC FarmacêuticoTHC:CBD Farmacêutico+1
  10. 2023

    Examining the use of cannabidiol and delta-9-tetrahydrocannabinol-based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double-blind randomised crossover trial

    FavorávelEnsaio Clínico Duplo-CegoDemênciaQualidade de Vida
  11. 2023

    Interplay Between Astroglial Endocannabinoid System and the Cognitive Dysfunction in Alzheimer's Disease

    InconclusivoEstudo Laboratorial
  12. 2023

    Multi-Targeting Intranasal Nanoformulation as a Therapeutic for Alzheimer's Disease

    FavorávelEstudo em AnimaisDisfunção CognitivaDoenças NeurodegenerativasDemência
  13. 2023

    Oral THC: CBD cannabis extract in main symptoms of Alzheimer disease: agitation and weight loss

    FavorávelEnsaio Clínico
  14. 2023

    Phytocannabinoids: Pharmacological effects, biomedical applications, and worldwide prospection

    InconclusivoMetanálise ClínicaDorCâncerAnsiedadeTHC FarmacêuticoTHC:CBD Farmacêutico+9
  15. 2023

    Preventing Neurocognitive Decline in Adults Aging with HIV: Implications for Practice and Research

    FavorávelMetanáliseInflamaçãoDisfunção CognitivaDoenças Neurodegenerativas+3
  16. 2023

    Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer's disease: A systematic review and meta-analysis of animal studies

  17. 2023

    Screening of Spirulina Components for Anti-Parkinson's and Anti-Alzheimer's Activity by in Silico Methods and Docking Studies

    FavorávelEstudo LaboratorialCâncerEstresse OxidativoDoenças NeurodegenerativasFicocianina+2
  18. 2023

    Synergetic effect of β-asarone and cannabidiol against Aβ aggregation in vitro and in vivo

  19. 2023

    The Cannabinoids, CBDA and THCA, Rescue Memory Deficits and Reduce Amyloid-Beta and Tau Pathology in an Alzheimer’s Disease-like Mouse Model

    FavorávelEstudo em AnimaisÁcido Canabidiólico (CBD-a)Ácido Tetraidrocanabinólico (THC-a)
  20. 2023

    The use of cannabidiol as a novel treatment for oral stereotypic behaviour (crib-biting) in a horse

    FavorávelEstudo em AnimaisDorInflamaçãoAnsiedadeEndocanabinoide (não especificado)+12
  21. 2023

    Use of non-medical cannabis in epilepsy: A scoping review

  22. 2022

    A review on structurally diversified synthesized molecules as monoacylglycerol lipase inhibitors and their therapeutic uses

  23. 2022

    A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment

    FavorávelMetanáliseDorCâncerAnsiedadeAnandamida (AEA)Tetraidrocanabinol (THC)+25
  24. 2022

    Activation of GPR55 attenuates cognitive impairment, oxidative stress, neuroinflammation, and synaptic dysfunction in a streptozotocin-induced Alzheimer's mouse model

  25. 2022

    Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial

    FavorávelEnsaio Clínico Duplo-CegoDepressãoDisfunção CognitivaPsicoseAnandamida (AEA)Palmitoiletanolamida (PEA)+3
  26. 2022

    An Ultra-Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer's Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model

    FavorávelEstudo em AnimaisDisfunção Cognitiva
  27. 2022

    Cannabidiol (CBD) treatment improves spatial memory in 14-month-old female TAU58/2 transgenic mice

    FavorávelEstudo em AnimaisAnsiedadeDisfunção CognitivaDoenças Neurodegenerativas
  28. 2022

    Cannabidiol Enhances Microglial Beta-Amyloid Peptide Phagocytosis and Clearance via Vanilloid Family Type 2 Channel Activation

    FavorávelEstudo LaboratorialDoenças NeurodegenerativasEndocanabinoide (não especificado)
  29. 2022

    Cannabidiol protects against Alzheimer's disease in C. elegans via ROS scavenging activity of its phenolic hydroxyl groups

    FavorávelEstudo em Animais
  30. 2022

    Cannabidiol reverses memory impairments and activates components of the Akt/GSK3β pathway in an experimental model of estrogen depletion

    FavorávelEstudo em AnimaisDisfunção CognitivaMenopausa
  31. 2022

    Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer’s Disease Rat Model: A Proof-of-Concept Study

    FavorávelEstudo em AnimaisInflamaçãoDoenças NeurodegenerativasSíndrome Metabólica+1
  32. 2022

    Cannabinoid CB 2 Receptors Modulate Microglia Function and Amyloid Dynamics in a Mouse Model of Alzheimer's Disease

  33. 2022

    Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report

    FavorávelMetanáliseInflamaçãoAnsiedadeDepressão+4
  34. 2022

    Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review

  35. 2022

    Cannabinoids: Therapeutic Use in Clinical Practice

  36. 2022

    Cannabis terpenes display variable protective and anti-aggregatory actions against neurotoxic β amyloid in vitro: highlighting the protective bioactivity of α-bisabolol in motorneuronal-like NSC-34 cells

    FavorávelEstudo LaboratorialDoenças Neurodegenerativas
  37. 2022

    Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications

  38. 2022

    Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents

  39. 2022

    Effect of Cannabidiol on the Neural Glyoxalase Pathway Function and Longevity of Several C. elegans Strains Including a C. elegans Alzheimer's Disease Model

    FavorávelEstudo LaboratorialLongevidade
  40. 2022

    Effect of the MAGL/FAAH Dual Inhibitor JZL-195 on Streptozotocin-Induced Alzheimer's Disease-like Sporadic Dementia in Mice with an Emphasis on Aβ, HSP-70, Neuroinflammation, and Oxidative Stress

  41. 2022

    Enhancing endocannabinoid signalling in astrocytes promotes recovery from traumatic brain injury

  42. 2022

    Gene Expression Analysis of the Endocannabinoid System in Presymptomatic APP/PS1 Mice

  43. 2022

    Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review

    FavorávelMetanálise ClínicaDependência QuímicaDependência — CannabisAnsiedade+5
  44. 2022

    Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders

  45. 2022

    Impact of the cannabinoid system in Alzheimer's diseases

  46. 2022

    Improved cognition impairment by activating cannabinoid receptor type 2: Modulating CREB/BDNF expression and impeding TLR-4/NFκBp65/M1 microglia signaling pathway in D-galactose-injected ovariectomized rats

  47. 2022

    In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils

    FavorávelEstudo LaboratorialDorCâncerInflamaçãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+14
  48. 2022

    Interacting binding insights and conformational consequences of the differential activity of cannabidiol with two endocannabinoid-activated G-protein-coupled receptors

    FavorávelMetanáliseEpilepsiaDoença de ParkinsonCanabinoides Sintéticos AM-x
  49. 2022

    Long-term Cannabis Users Show Lower Cognitive Reserves and Smaller Hippocampal Volume in Midlife

  50. 2022

    Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice

  51. 2022

    LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoAnsiedadeAyahuasca+6
  52. 2022

    Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

  53. 2022

    Medical Cannabis and Psychiatric Disorders: Implications for Psychiatric Nurses

    InconclusivoMetanáliseAnsiedadeTEPTDemência+2
  54. 2022

    Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of APP Swe /PS1ΔE9 Transgenic Female Mice

    FavorávelEstudo em AnimaisInflamaçãoAnsiedadeDisfunção Cognitiva+4
  55. 2022

    Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders

  56. 2022

    Neuroprotective effect of alpha-pinene is mediated by suppression of the TNF-α/NF-κB pathway in Alzheimer's disease rat model

    FavorávelEstudo em AnimaisInflamaçãoAnsiedadeDisfunção CognitivaMedicina Mente-Corpo+4
  57. 2022

    Orchestration of the circadian clock and its association with Alzheimer's disease: Role of endocannabinoid signaling

  58. 2022

    Parkinson’s Disease and Dementia with Lewy Bodies, Patients Under Treatment with Standardized Extracts Enriched in Cannabidiol and Cannabigerol: Descriptive Observations in Preparation for a Phase 2a Clinical Trial

    FavorávelMetanáliseDorAnsiedadePsicoseTetraidrocanabinol (THC)Canabigerol (CBG)+3
  59. 2022

    Pharmacological Activation of GPR55 Improved Cognitive Impairment Induced by Lipopolysaccharide in Mice

  60. 2022

    Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice

  61. 2022

    Phytol loaded PLGA nanoparticles ameliorate scopolamine-induced cognitive dysfunction by attenuating cholinesterase activity, oxidative stress and apoptosis in Wistar rat

    FavorávelEstudo em AnimaisDisfunção Cognitiva
  62. 2022

    Protective Effects of Cannabidiol on Chemotherapy-Induced Oral Mucositis via the Nrf2/Keap1/ARE Signaling Pathways

    FavorávelEstudo em AnimaisCâncerInflamaçãoDoenças Cardiovasculares (DCV)+6
  63. 2022

    The Effect of Cannabidiol Coated by Nano-Chitosan on Learning and Memory, Hippocampal CB1 and CB2 Levels, and Amyloid Plaques in an Alzheimer's Disease Rat Model

    FavorávelEstudo em AnimaisDoenças NeurodegenerativasDemência
  64. 2022

    The Effect of Oleoylethanolamide (OEA) Add-On Treatment on Inflammatory, Oxidative Stress, Lipid, and Biochemical Parameters in the Acute Ischemic Stroke Patients: Randomized Double-Blind Placebo-Controlled Study

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoAnsiedadeAnandamida (AEA)Hidrolase de Amidas de Ácidos Graxos (FAAH)+7
  65. 2022

    The Food Additive β-Caryophyllene Exerts Its Neuroprotective Effects Through the JAK2-STAT3-BACE1 Pathway

    FavorávelEstudo LaboratorialDoenças Neurodegenerativas
  66. 2022

    The Memory Benefit to Aged APP/PS1 Mice from Long-Term Intranasal Treatment of Low-Dose THC

  67. 2022

    The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials

    FavorávelMetanálise ClínicaDorCâncerEfeitos Adversos da CannabisTHC Farmacêutico+7
  68. 2022

    Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence

    FavorávelMetanálise ClínicaDorInflamaçãoDisfunção CognitivaPalmitoiletanolamida (PEA)+8
  69. 2022

    Treatment of Ovarian Hyperstimulation Syndrome in a Mouse Model by Cannabidiol, an Angiogenesis Pathway Inhibitor

    FavorávelEstudo em AnimaisDorCâncerInflamação+16
  70. 2022

    What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?

  71. 2021

    (m)RVD-hemopressin (α) and (m)VD-hemopressin (α) improve the memory-impairing effect of scopolamine in novel object and object location recognition tasks in mice

    FavorávelEstudo em AnimaisCanabinoide Sintético (não especificado)
  72. 2021

    A Functionalized Octahedral Palladium Nanozyme as a Radical Scavenger for Ameliorating Alzheimer's Disease

    FavorávelEstudo em AnimaisEstresse Oxidativo
  73. 2021

    A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Discovering Novel Therapeutics in the Flavours and Fragrances of Cannabis

    FavorávelMetanáliseInflamaçãoAnsiedadeDepressão+5
  74. 2021

    Activation of GPR55 attenuates cognitive impairment and neurotoxicity in a mouse model of Alzheimer's disease induced by Aβ 1-42 through inhibiting RhoA/ROCK2 pathway

  75. 2021

    Adolescent binge-ethanol accelerates cognitive impairment and β-amyloid production and dysregulates endocannabinoid signaling in the hippocampus of APP/PSE mice

  76. 2021

    Ameliorative effect of myrcene in mouse model of Alzheimer's disease

    FavorávelEstudo em Animais
  77. 2021

    Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhibition in Monocytes/Macrophages from Alzheimer's Disease Patients

    FavorávelEstudo LaboratorialHidrolase de Amidas de Ácidos Graxos (FAAH)
  78. 2021

    Attitudes, beliefs, and changing trends of cannabidiol (CBD) oil use among caregivers of individuals with Alzheimer's disease

    FavorávelMetanálise
  79. 2021

    Cannabidiol - A phytocannabinoid that widely affects sphingolipid metabolism under conditions of brain insulin resistance

    FavorávelEstudo em AnimaisDoenças NeurodegenerativasObesidadeDiabetes+1
  80. 2021

    Cannabidiol (CBD) enhanced the hippocampal immune response and autophagy of APP/PS1 Alzheimer's mice uncovered by RNA-seq

    FavorávelEstudo em Animais
  81. 2021

    Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer's Disease

    FavorávelEstudo em AnimaisDisfunção CognitivaDemência
  82. 2021

    Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action

    FavorávelMetanáliseCâncerEpilepsiaDoenças Neurodegenerativas+1
  83. 2021

    Cannabidiol regulates CB1-pSTAT3 signaling for neurite outgrowth, prolongs lifespan, and improves health span in Caenorhabditis elegans of Aβ pathology models

    FavorávelEstudo em Animais
  84. 2021

    Cannabinoid control of hippocampal functions: the where matters

  85. 2021

    Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

    InconclusivoEstudo em AnimaisDoenças Neurodegenerativas
  86. 2021

    Cannabinoids for Agitation in Alzheimer's Disease

    FavorávelMetanáliseDemência
  87. 2021

    Cannabinoids for the treatment of dementia

  88. 2021

    Cannabinoids in the management of frontotemporal dementia: a case series

    FavorávelMetanáliseDemênciaTOC
  89. 2021

    Cannabis Sativa L. Flower and Bud Extracts inhibited In vitro Cholinesterases and b-Secretase Enzymes Activities: Possible Mechanisms of Cannabis use in Alzheimer Disease

    FavorávelEstudo Laboratorial
  90. 2021

    Cannabis Use among Persons with Dementia and Their Caregivers: Lighting up an Emerging Issue for Clinical Gerontologists

    FavorávelMetanáliseDemência
  91. 2021

    Component of Cannabis, Cannabidiol, as a Possible Drug against the Cytotoxicity of Aβ(31–35) and Aβ(25–35) Peptides: An Investigation by Molecular Dynamics and Well-Tempered Metadynamics Simulations

    FavorávelEstudo Laboratorial
  92. 2021

    Destabilization of the Alzheimer's amyloid-β protofibrils by THC: A molecular dynamics simulation study

    FavorávelEstudo Laboratorial
  93. 2021

    Effects of a Novel GPR55 Antagonist on the Arachidonic Acid Cascade in LPS-Activated Primary Microglial Cells

    FavorávelEstudo LaboratorialInflamaçãoDepressãoCanabinoide Sintético (não especificado)
  94. 2021

    Emerging potential of cannabidiol in reversing proteinopathies

    FavorávelMetanáliseEsclerose MúltiplaDoença de ParkinsonDoença de Huntington+1
  95. 2021

    Emerging role of cannabinoids and synthetic cannabinoid receptor 1/cannabinoid receptor 2 receptor agonists in cancer treatment and chemotherapy-associated cancer management

    FavorávelMetanáliseDorCâncerAnsiedade+4
  96. 2021

    Endocannabinoid Metabolism and Traumatic Brain Injury

  97. 2021

    Endocannabinoid-mediated neuromodulation in the main olfactory bulb at the interface of environmental stimuli and central neural processing

    FavorávelMetanáliseDoença de ParkinsonEndocanabinoide (não especificado)
  98. 2021

    Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer's Disease

    FavorávelEstudo em AnimaisMonoacilglicerol Lipase (MAGL)
  99. 2021

    Lavender and coriander essential oils and their main component linalool exert a protective effect against amyloid-β neurotoxicity

    FavorávelEstudo LaboratorialDemênciaMedicina Mente-Corpo
  100. 2021

    Linalool Alleviates A β 42-Induced Neurodegeneration via Suppressing ROS Production and Inflammation in Fly and Rat Models of Alzheimer's Disease

    FavorávelEstudo em AnimaisInflamaçãoDoenças Neurodegenerativas
  101. 2021

    Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review

  102. 2021

    Neuroprotective Potential of Limonene and Limonene Containing Natural Products

    FavorávelMetanáliseAnsiedadeEpilepsiaDoenças Neurodegenerativas+2
  103. 2021

    Novel cannabidiol−carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease

    FavorávelMetanálise
  104. 2021

    Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases

  105. 2021

    Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition

  106. 2021

    Potential and Limits of Cannabinoids in Alzheimer's Disease Therapy

    InconclusivoMetanálise
  107. 2021

    Progress on the application of positron emission tomography imaging of cannabinoid type 1 receptor in neuropsychiatric diseases

  108. 2021

    Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases

    FavorávelMetanáliseDoença de ParkinsonDoença de Huntington
  109. 2021

    Roles of Cannabidiol in the treatment and prevention of Alzheimer's disease by multi-target actions

    FavorávelMetanálise
  110. 2021

    The cannabinoid system and microglia in health and disease

  111. 2021

    The Endocannabinoid System: A Bridge between Alzheimer's Disease and Gut Microbiota

  112. 2021

    The Neuroprotective properties, Functions and Roles of Cannabis sativa in selected diseases related to the Nervous System

  113. 2021

    The Role of Cannabidiol in Neurological Disorders

  114. 2021

    The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?

    FavorávelMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  115. 2021

    The role of fatty acid amide hydrolase enzyme inhibitors in Alzheimer's disease

  116. 2021

    Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease

  117. 2020

    A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia

    InconclusivoMetanálise ClínicaDemência
  118. 2020

    A systematic review of minor phytocannabinoids with promising neuroprotective potential

  119. 2020

    Activation of cannabinoid receptor 2 protects rat hippocampal neurons against Aβ-induced neuronal toxicity

    FavorávelEstudo em AnimaisDemênciaCanabinoides Sintéticos JWH-x
  120. 2020

    An optimized spectrophotometric assay reveals increased activity of enzymes involved in 2-arachidonoyl glycerol turnover in the cerebral cortex of a rat model of Alzheimer's disease

    FavorávelEstudo em Animais2-Araquidonoilglicerol (2-AG)Monoacilglicerol Lipase (MAGL)
  121. 2020

    Astrocytic palmitoylethanolamide pre-exposure exerts neuroprotective effects in astrocyte-neuron co-cultures from a triple transgenic mouse model of Alzheimer's disease

  122. 2020

    Attenuation of Oxidative Stress by Cannabinoids and Cannabis Extracts in Differentiated Neuronal Cells

  123. 2020

    Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders?

  124. 2020

    Cannabidiol (CBD)

    FavorávelMetanáliseInflamaçãoAnsiedadeEpilepsia+4
  125. 2020

    Cannabinoid-profiled agents improve cell survival via reduction of oxidative stress and inflammation, and Nrf2 activation in a toxic model combining hyperglycemia+Aβ 1-42 peptide in rat hippocampal neurons

    FavorávelEstudo LaboratorialAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
  126. 2020

    Chronic cannabidiol (CBD) treatment did not exhibit beneficial effects in 4-month-old male TAU58/2 transgenic mice

    InconclusivoEstudo em Animais
  127. 2020

    Crosstalk between the M 1 muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer's disease?

    FavorávelMetanálise
  128. 2020

    Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review

    FavorávelMetanáliseDoença de Parkinson
  129. 2020

    Debunking Cannabidiol as a Treatment for COVID-19: Time for the FDA to Adopt a Focused Deterrence Model?

    DesfavorávelMetanáliseCâncerDepressãoDiabetes+1
  130. 2020

    Effectiveness of Cannabinoids for Treatment of Dementia: A Systematic Review of Randomized Controlled Trials

    FavorávelMetanálise ClínicaDisfunção CognitivaTHC Farmacêutico
  131. 2020

    Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease

    FavorávelMetanáliseDorInflamaçãoDisfunção Cognitiva+2
  132. 2020

    Endocannabinoid system alterations in Alzheimer's disease: A systematic review of human studies

    InconclusivoMetanálise
  133. 2020

    Food supplements based on palmitoylethanolamide plus hydroxytyrosol from olive tree or Bacopa monnieri extracts for neurological diseases

  134. 2020

    From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases

    FavorávelMetanáliseInflamaçãoEstresse OxidativoDoenças Neurodegenerativas+1
  135. 2020

    GPR6 Structural Insights: Homology Model Construction and Docking Studies

  136. 2020

    Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity

  137. 2020

    Is 1,8-Cineole-Rich Extract of Small Cardamom Seeds More Effective in Preventing Alzheimer's Disease than 1,8-Cineole Alone?

    FavorávelEstudo LaboratorialDoenças NeurodegenerativasMedicina Mente-Corpo
  138. 2020

    Isomeric O-methyl cannabidiolquinones with dual BACH1/NRF2 activity

    FavorávelEstudo LaboratorialInflamaçãoEstresse OxidativoDoenças Neurodegenerativas+3
  139. 2020

    Melatonin and cannabinoids: mitochondrial-targeted molecules that may reduce inflammaging in neurodegenerative diseases

    FavorávelMetanáliseInflamaçãoEstresse OxidativoDoenças Neurodegenerativas+2
  140. 2020

    Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease

  141. 2020

    Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease

    FavorávelMetanáliseEpilepsia
  142. 2020

    Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries—A Systematic Review

  143. 2020

    Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission?

    InconclusivoMetanáliseAnsiedadeEpilepsiaDoença de Parkinson+2
  144. 2020

    Targeting Cannabinoid Receptor Activation and BACE-1 Activity Counteracts TgAPP Mice Memory Impairment and Alzheimer's Disease Lymphoblast Alterations

  145. 2020

    The Cannabinoid Receptor Agonist WIN55,212-2 Ameliorates Hippocampal Neuronal Damage After Chronic Cerebral Hypoperfusion Possibly Through Inhibiting Oxidative Stress and ASK1-p38 Signaling

  146. 2020

    The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study

    FavorávelEnsaio Clínico Duplo-CegoDependência — CannabisAnsiedadePsicoseCanabinoide Sintético (não especificado)+5
  147. 2020

    The Endocannabinoid System May Modulate Sleep Disorders in Aging

  148. 2019

    24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone

  149. 2019

    A Review on Studies of Marijuana for Alzheimer's Disease - Focusing on CBD, THC

  150. 2019

    Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation

    FavorávelEnsaio Clínico Duplo-CegoInflamaçãoEstresse OxidativoDoenças NeurodegenerativasTHC Farmacêutico
  151. 2019

    Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimer’s Disease

    FavorávelEstudo Laboratorial
  152. 2019

    Cannabinoid as Beneficial Replacement Therapy for Psychotropics to Treat Neuropsychiatric Symptoms in Severe Alzheimer's Dementia: A Clinical Case Report

    FavorávelMetanáliseTHC Farmacêutico
  153. 2019

    Cannabinoids and Dementia: A Review of Clinical and Preclinical Data

  154. 2019

    GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol

    FavorávelEstudo LaboratorialDoença de Parkinson
  155. 2019

    Impact of Cannabis-Based Medicine on Alzheimer's disease by Focusing on the Amyloid β- Modifications: A Systematic Study

    FavorávelMetanálise
  156. 2019

    Prescription of a THC/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva

    FavorávelEnsaio ClínicoDisfunção CognitivaDoenças NeurodegenerativasDemência
  157. 2019

    Priority Considerations for Medicinal Cannabis-Related Research

    FavorávelMetanáliseDorCâncerAnsiedade+16
  158. 2019

    Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease

    FavorávelEnsaio Clínico Duplo-CegoTHC Farmacêutico
  159. 2019

    Selective Modulator of Cannabinoid Receptor Type 2 Reduces Memory Impairment and Infarct Size During Cerebral Hypoperfusion and Vascular Dementia

    FavorávelEstudo em AnimaisDisfunção CognitivaDoenças NeurodegenerativasDemência
  160. 2019

    The Endocannabinoid System of Animals

  161. 2019

    US Veterinarians' Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions

    FavorávelMetanáliseDorCâncerInflamaçãoCBD Farmacêutico+16
  162. 2018

    A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders

  163. 2018

    Biphasic effects of THC in memory and cognition.

  164. 2018

    Cannabinoid signalling in embryonic and adult neurogenesis: possible implications for psychiatric and neurological disorders.

  165. 2018

    Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia

    FavorávelMetanáliseDoenças NeurodegenerativasPerda de Apetite
  166. 2018

    Cannabis Therapeutics and the Future of Neurology

  167. 2018

    Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model.

    FavorávelEstudo em Animais
  168. 2018

    In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid

  169. 2018

    Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's disease and Less Well-Known Diseases.

  170. 2018

    Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model

    FavorávelEstudo em AnimaisCâncerInflamaçãoEstresse Oxidativo+8
  171. 2018

    Paeoniflorin exerts neuroprotective effects by modulating the M1/M2 subset polarization of microglia/macrophages in the hippocampal CA1 region of vascular dementia rats via cannabinoid receptor 2.

  172. 2018

    Palmitoylethanolamide Blunts Amyloid-β42-Induced Astrocyte Activation and Improves Neuronal Survival in Primary Mouse Cortical Astrocyte-Neuron Co-Cultures

    FavorávelEstudo LaboratorialInflamaçãoDoenças NeurodegenerativasPalmitoiletanolamida (PEA)
  173. 2018

    Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease: In Vitro and In Vivo Evidence

    FavorávelEstudo em AnimaisDoenças NeurodegenerativasPalmitoiletanolamida (PEA)
  174. 2018

    Perillyl Alcohol Alleviates Amyloid-β Peptides-Induced Mitochondrial Dysfunction and Cytotoxicity in SH-SY5Y Cells

    FavorávelEstudo Laboratorial
  175. 2018

    Phytol-loaded PLGA Nanoparticle as a Modulator of Alzheimer's Toxic Aβ Peptide Aggregation and Fibrillation Associated With Impaired Neuronal Cell Function

    FavorávelEstudo LaboratorialDisfunção CognitivaEstresse OxidativoMedicina Mente-Corpo
  176. 2018

    The protective effects of β-caryophyllene on LPS-induced primary microglia M1/M2 imbalance: A mechanistic evaluation.

    FavorávelEstudo LaboratorialInflamaçãoEsclerose Múltipla
  177. 2018

    Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease by exerting anti-inflammatory and neuroprotective effects

    FavorávelEstudo em AnimaisDoenças NeurodegenerativasPalmitoiletanolamida (PEA)
  178. 2017

    A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia

    FavorávelMetanáliseInflamaçãoDisfunção CognitivaPsicose+5
  179. 2017

    Cannabinoid Receptor 2 Signaling In Neurodegenerative Disorders: From Pathogenesis To A Promising Therapeutic Target

  180. 2017

    Deletion of Type-2 Cannabinoid Receptor Induces Alzheimer's Disease-Like Tau Pathology and Memory Impairment Through AMPK/GSK3β Pathway

    FavorávelEstudo em AnimaisDoenças NeurodegenerativasEndocanabinoide (não especificado)
  181. 2017

    Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease.

    FavorávelMetanálise
  182. 2017

    GPR3 And GPR6, Novel Molecular Targets For Cannabidiol

    FavorávelEstudo LaboratorialDoença de Parkinson
  183. 2017

    Neurological Aspects Of Medical Use Of Cannabidiol

    FavorávelMetanáliseEpilepsiaDisfunção CognitivaEsclerose Múltipla+4
  184. 2017

    The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations

    FavorávelMetanáliseDorInflamaçãoDor — CrônicaPalmitoiletanolamida (PEA)+7
  185. 2016

    Activity Of Muscarinic, Galanin And Cannabinoid Receptors In The Prodromal And Advanced Stages In The Triple Transgenic Mice Model Of Alzheimer's Disease

    FavorávelEstudo em Animais
  186. 2016

    Amyloid Proteotoxicity Initiates An Inflammatory Response Blocked By Cannabinoids

  187. 2016

    Cannabinoids in Palliative Care: Systematic Review and Meta-Analysis of Efficacy, Tolerability and Safety

    InconclusivoMetanálise ClínicaDorCâncerInsônia e Distúrbios do Sono+4
  188. 2016

    Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model

    FavorávelEstudo em AnimaisDemência
  189. 2016

    Endocannabinoid System: A Multi-Facet Therapeutic Target.

  190. 2016

    Endocannabionoid System In Neurological Disorders

  191. 2016

    Linalool reverses neuropathological and behavioral impairments in old triple transgenic Alzheimer’s mice.

    FavorávelEstudo em Animais
  192. 2016

    Safety And Efficacy Of Medical Cannabis Oil For Behavioral And Psychological Symptoms Of Dementia: An-Open Label, Add-On, Pilot Study

    FavorávelMetanáliseDisfunção CognitivaDemência
  193. 2016

    Type-2 cannabinoid receptors in neurodegeneration

  194. 2015

    Cannabinoids In Late-onset Alzheimer's Disease

    FavorávelMetanáliseDisfunção Cognitiva
  195. 2015

    Cannabinoids In Neurodegenerative Disorders And Stroke/Brain Trauma: From Preclinical Models To Clinical Applications

    FavorávelMetanáliseDoenças NeurodegenerativasDoença de ParkinsonAVC+3
  196. 2015

    Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review

    FavorávelMetanáliseDorDependência QuímicaDependência — Cannabis+16
  197. 2015

    Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others

  198. 2015

    Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia

    FavorávelEnsaio Clínico Duplo-CegoDisfunção CognitivaDemênciaTetraidrocanabinol (THC)THC Farmacêutico
  199. 2015

    Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDisfunção CognitivaTHC Farmacêutico+3
  200. 2015

    Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial

    InconclusivoEnsaio Clínico Duplo-CegoTranstornos de ComportamentoDemênciaTetraidrocanabinol (THC)
  201. 2014

    The Influence Of Cannabinoids On Generic Traits Of Neurodegeneration

  202. 2014

    β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARγ pathway.

    FavorávelEstudo em AnimaisCanabinoides Sintéticos AM-x
  203. 2013

    Default mode network in the effects of Δ9-Tetrahydrocannabinol (THC) on human executive function

    DesfavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisDisfunção CognitivaPsicoseTetraidrocanabinol (THC)+2
  204. 2012

    Mast cell–glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide

  205. 2011

    Borneol alleviates oxidative stress via upregulation of Nrf2 and Bcl-2 in SH-SY5Y cells

    FavorávelEstudo LaboratorialEstresse Oxidativo
  206. 2011

    Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress.

  207. 2011

    Cognitive Reserve in Aging.

    FavorávelMetanálise
  208. 2011

    Salvianic borneol ester reduces β-amyloid oligomers and prevents cytotoxicity

    FavorávelEstudo Laboratorial
  209. 2011

    Targets of curcumin

    FavorávelMetanáliseCâncerInflamaçãoDoenças Cardiovasculares (DCV)Cúrcuma+16
  210. 2010

    Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders

  211. 2010

    Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality

  212. 2010

    Therapeutic Potential Of Non-Psychotropic Cannabidiol In Ischemic Stroke

    FavorávelMetanáliseDisfunção CognitivaDoença de ParkinsonArtrite+2
  213. 2009

    Acetylcholinesterase and butyrylcholinesterase inhibitory activity of Pinus species essential oils and their constituents

    FavorávelEstudo Laboratorial
  214. 2009

    The Activation Of Cannabinoid CB2 Receptors Stimulates In Situ And In Vitro Beta-amyloid Removal By Human Macrophages

    FavorávelEstudo LaboratorialDemênciaCanabinoides Sintéticos JWH-x
  215. 2008

    Targeting the endocannabinoid system: to enhance or reduce?

  216. 2008

    The Cannabinoid Receptor Agonist Nabilone For The Treatment Of Dementia-related Agitation

    FavorávelMetanáliseTHC Farmacêutico
  217. 2008

    The Role Of The Endocannabinoid System In Alzheimer's Disease: Facts And Hypotheses

    FavorávelMetanálise
  218. 2007

    Alzheimer's disease; taking the edge off with cannabinoids?

    FavorávelMetanálise
  219. 2007

    Cannabinoids in health and disease

  220. 2007

    Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies

    FavorávelMetanáliseDoenças NeurodegenerativasDoença de ParkinsonÔmega-3
  221. 2006

    A Molecular Link Between The Active Component Of Marijuana And Alzheimer's Disease Pathology

    FavorávelEstudo Laboratorial
  222. 2006

    Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.

  223. 2005

    Prevention Of Alzheimer's Disease Pathology By Cannabinoids: Neuroprotection Mediated By Blockade Of Microglial Activation

    FavorávelEstudo em AnimaisCanabinoides Sintéticos WIN-xCanabinoides Sintéticos JWH-x+1
  224. 2004

    Neuroprotective Effect Of Cannabidiol, A Non-psychoactive Component From Cannabis Sativa, On Beta-amyloid-induced Toxicity In PC12 Cells

    FavorávelEstudo LaboratorialEstresse Oxidativo
  225. 2004

    Role of the endocannabinoid system in Alzheimer's disease: new perspectives.

    FavorávelEstudo Laboratorial
  226. 2003

    Cannabinoid CB2 Receptors And Fatty Acid Amide Hydrolase Are Selectively Overexpressed In Neuritic Plaque-associated Glia In Alzheimer's Disease Brains

    FavorávelEstudo LaboratorialHidrolase de Amidas de Ácidos Graxos (FAAH)
  227. 2002

    Anandamide And Noladin Ether Prevent Neurotoxicity Of The Human Amyloid-beta Peptide

    FavorávelEstudo LaboratorialAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  228. 2000

    In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes.

    FavorávelEstudo LaboratorialDisfunção CognitivaEsclerose MúltiplaDoença de Parkinson
  229. 2000

    Linalool modifies the nicotinic receptor-ion channel kinetics at the mouse neuromuscular junction.

    FavorávelEstudo em AnimaisDependência QuímicaDependência — Nicotina
  230. 1999

    Cannabinoids as antioxidants and neuroprotectants.

  231. 1997

    Effects Of Dronabinol On Anorexia And Disturbed Behavior In Patients With Alzheimer's Disease

    FavorávelEnsaio Clínico Duplo-CegoAnorexia (perda de apetite)Tetraidrocanabinol (THC)THC Farmacêutico
  232. 1996

    Tau protein after delta-9-tetrahydrocannabinol in a human neuroblastoma cell line

    InconclusivoEstudo LaboratorialCâncerCâncer — Neuroblastoma
  233. 1890

    Cannabis Indica

    FavorávelMetanáliseDorDor — CrônicaInsônia e Distúrbios do Sono+6

Continue por aqui

Perguntas frequentes

Quantos estudos sobre doença de alzheimer estão indexados no acervo?
São 233 estudos, publicados entre 1890 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 110 · Estudo em Animais: 54 · Estudo Laboratorial: 42 · Ensaio Clínico Duplo-Cego: 12 · Metanálise Clínica: 11 · Ensaio Clínico: 4. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 209 favoráveis, 20 inconclusivos e 4 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Doença de Alzheimer — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/doenca-de-alzheimer/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Doença de Alzheimer — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/doenca-de-alzheimer/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.